Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Hypercholesterolemia and CYP2C9[original query] |
---|
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics 2013 Aug 14 (11): 1283-94. Lee Hon-Kit, Hu Miao, Lui Sandra Sh, Ho Chung-Shun, Wong Chun-Kwok, Tomlinson Bri |
CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy. Clinical laboratory 2015 61 (9): 1317-24. Lin Jiayao, Zhang Yu, Zhou Houguang, Wang Xinqing, Wang Wenw |
A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions. Pharmacogenomics and personalized medicine 2020 3 13 59-70. Calderon-Ospina Carlos Alberto, Hernández-Sómerson Mario, García Ana María, Mejia Adriana, Tamayo-Agudelo Caroll, Laissue Paul, Fonseca Mendoza Dora Jane |
- Page last reviewed:Feb 1, 2024
- Content source: